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ABSTRACT 
Traditional Non-steroidal Anti-Inflammatory Drugs (NAIDs) have been widely used to deal with many 
inflammatory conditions in veterinary medicine. Nowadays however, as the quality of life of animals is 
improved, new drug options need to be explored. In this review, the authors report on recent trends and the 
application of the active ingredients labeled for veterinary purposes. 
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1. INTRODUCTION 
In basic terms, inflammation is a protective reaction 
of the body against external and internal stimuli. In the 
acute phase, it serves to remove triggering agents in 
addition to restoring tissue following damage. However, 
if the inflammatory process becomes overwhelming, it 
results in pain through activation of nociceptors by 
various inflammatory mediators and eventually it can 
become life threatening and requiring of clinical 
intervention (Dubin and Patapoutian, 2010). 
The Nonsteroidal Anti-Inflammatory Drugs 
(NSAIDs) are used to treat pain, fever and inflammation 
in various diseases. Although the properties of NSAIDs 
may vary slightly between the diverse classes and 
generations, the main mechanism of action involves 
inhibition of Cyclo-Oxygenase (COX) in various organs. 
COX is the enzyme that converts Arachidonic Acid (AA) 
to form prostanoids, which are essential biological 
mediators including Prostaglandins (PG) and 
Thromboxanes (TX). In 1990, two decades after the 
discovery of COX, it was revealed that COX exists as 
two isoforms, COX-1 and COX-2 (Meek et al., 2010; 
Vonkeman and Laar, 2010). In brief, COX-1 is a 
constitutive enzyme found in many organs under normal 
conditions, while COX-2 is an enzyme up-regulated 
during inflammatory processes. Additionally in 2002, the 
third COX isoform (COX-3) was discovered. It is 
encoded by the same gene as COX-1, but COX-3, as a 
clinical target, is yet to be fully understood (Botting, 
2003; Perrone et al., 2010). 
In general, COX-1 is thought to be beneficial to the 
body’s homeostasis with functions including 
maintenance of mucosal epithelium integrity, thus, its 
inhibition readily leads to gastric ulcers (Buvanendran, 
2012). Inhibition of COX-2 only could decrease 
production of prostanoids such as PGE2 and PGI2 that 
are just involved in inflammatory and pathological 
processes, as well as ameliorate pain generation 
(Agarwal et al., 2009). Therefore, many clinical trials 
with NSAIDs focus on the selective inhibition of COX-2 
enzymes because of the superior safety profile resulting 
from the COX-1 sparing effect. 
Nowadays, there is a growing interest in animal 
welfare. Owners consider their pets as members of their 
families. The changed breeding environment and 
extended life span of pets has meant that they are 
predisposed to an extended spectrum of diseases for 
which owners are demanding a higher level of care. 
These trends have been an impetus for the development 
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of more effective and innovative veterinary therapies 
(Giorgi, 2012; Giorgi et al., 2012a; Giorgi and Yun, 
2012). However, veterinarians still have a reduced drug 
armamentarium compared to their human counterparts, 
thus, many studies have been conducted on the use of 
human medicine in the veterinary field (Giorgi et al., 
2012b; Lavy et al., 2011). As use of selective COX-2 
inhibitors (coxibs) became more prominent in human 
medicine, it followed that many selective inhibitors 
were introduced into clinical use for the veterinary 
market. Nowadays, many pharmaceutical companies 
have their own coxib drugs (“me too” drugs) and 
some of these active ingredients have been recently 
launched on the veterinary market. 
However, animal species differences in factors such 
as the sensitivity and disposition of certain drugs could 
evoke unexpected results if they are used without any 
understanding of the drugs’ behaviour in the target 
species (Martignoni et al., 2006; Giorgi et al., 2011; 
Toutain et al., 1997). In addition, to the best of the 
Authors’ knowledge, the cardiovascular effects of coxibs 
during protracted therapy have not described in animals. 
In contrast, in the human field, coxibs have been reported 
to produce adverse effects on cardiovascular system such 
as thrombotic disorders including cerebral vascular events 
and myocardial infarction (Cairns, 2007; Batlouni, 2010). 
Furthermore, animals can be more sensitive to coxibs than 
humans due to differences in drug metabolism, absorption 
and enterohepatic recirculation (Bergh and Budsberg, 
2005). For these reasons, knowing the pharmacological 
properties, pharmacokinetic/pharmacodynamic and safety 
profile of each drug is essential in order to use veterinary 
coxibs appropriately. 
1.1. Classification of Coxibs 
The coxibs are a subclass of NSAID which have a 
COX-1 sparing effects. Because of steric hindrance, the 
COX-1 active site is smaller than that of COX-2. The 
bulky structure of coxibs restricts their inhibition of 
COX-1 but allows for complete inhibition of the COX-2 
pathway. The classification of NSAIDs is expressed as 
COX-2 selective, COX-2 specific, or COX-2 
preferential. This indicates the drug selectivity for COX-
2 and it is determined through calculation of the 
inhibitory concentration (IC50) COX-1:COX-2 ratio 
(Bergh and Budsberg, 2005; Vane and Warner, 2000). 
However, these ratios have not been fully quantified and 
ratios for the same compound can be inconsistent, as the 
assays used were considerably different (Livingston, 
2000; Pairet and Ryn, 1998). 
Coxibs are regarded as a third generation of 
NSAIDs (Sternon, 2001). In the human field, several 
coxibs have been launched. The first to be launched 
were rofecoxib and celecoxib, these have been 
categorized as first generation. The newest active 
ingredients (valdecoxib, parecoxib, etoricoxib and 
lumiracoxib) have been classified as second generation 
and possess a stronger selectivity for the COX-2 
enzyme inhibition (Stichtenoth, 2004; Andersohn et al., 
2006). In veterinary medicine deracoxib (2002), 
firocoxib (2007), mavacoxib (2008) and robenacoxib 
(2009) have been introduced for animal use (Bergh and 
Budsberg, 2005). Recently, cimicoxib (2011) has also 
been introduced for the veterinary market from the 
human field (Emmerich, 2012). 
1.2. Deracoxib 
Deracoxib (Deramaxx®; Novartis) was the first coxib 
to be approved in veterinary medicine (Papich, 2008). 
Deracoxib contains a sulfonamide moiety. Chemically it 
is a 4-[3-(difluoromethyl)-5-(3-fluoro-4-
methoxyphenyl)-1H-pyrazole-1-yl] benzenesulfonamide 
and its molecular weight is 397.38 g moL−1. Deracoxib is 
categorized as a diarylheterocycle drug, these exert a 
time-dependent pseudo-irreversible inhibition of 
COX-2 (Walker et al., 2001). Deracoxib was initially 
approved for postoperative orthopedic pain in dogs at 
3-4 mg kg−1 by oral (PO) daily dose for a maximum of 
7 days. In 2003, deracoxib was also approved for 
chronic administration at a dosage of 1-2 mg kg−1 PO 
once daily (Smith, 2003).  
In in vitro evaluations, among the coxibs, deracoxib 
was determined as a highly selective COX-2 inhibitor 
with a COX-1/COX-2 ratio of 1275 in purified enzymes 
assay (Gierse et al., 2002). However when tested using 
canine whole blood, the COX-1/COX-2 ratio was only 12 
(McCann et al., 2004). This inconsistency resulted from 
the different types of cells with different cell conditions 
being used in each assay (Vane and Botting, 1995). 
In another study using dogs, deracoxib showed the 
same degree of COX-1 and COX-2 inhibition as 
carprofen (COX-2 preferential drug), despite a wide 
variation of COX-1/COX-2 inhibitory ratios between the 
two drugs being found in in vitro assays (Sessions et al., 
2005). These discordance results between in vivo and in 
vitro studies suggest that the in vitro results do not 
provide a quantitative measure of difference in efficacy 
or safety (Papich, 2008). 
In the pharmacokinetic evaluation after oral 
administration of deracoxib (2~3 mg kg−1) in dogs, 
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deracoxib had a protein binding affinity of over 90%. It 
also underwent hepatic biotransformation with an 
elimination half-life of 3 h, using biliary excretion as a 
major excretion route (Smith, 2003). After high-dose 
administration (8 mg kg−1) however, a non-linear 
elimination has been shown: deracoxib loses its COX-2 
selectivity and starts to inhibit COX-1 also (DCT, 2003). 
The nonlinearity at high doses might result from 
saturation of the metabolizing enzymes. In other species 
treated with deracoxib including cats (1 mg kg−1) and 
horses (1~2 mg kg−1), a longer half-life (7.9 and 12 h, 
respectively) than dogs was reported (Davis et al., 
2011; Gassel et al., 2006). In cats and horses the 
hepatic enzymes, which participate in 
biotransformation of deracoxib, may be present at 
lower concentrations than in dogs and might therefore 
be saturated at lower concentrations, which leads to 
the longer half-life (Davis et al., 2011). 
Clinical trials in dogs showed that deracoxib (1~2 mg 
kg−1 PO for 3 days) was able to reduce postoperative pain 
and inflammation after dental extraction surgery 
(Bienhoff et al., 2012). In addition, Millis et al. (2002) 
reported that the administration of deracoxib (1, 3, or 10 
mg kg−1 PO) was more effective in reducing pain 
associated with urate crystal-induced synovitis than 
carprofen (2.2 mg kg−1 PO). Deracoxib treatment also 
showed no significant adverse effects (Millis et al., 2002).  
After 28 days of once daily administration of 
deracoxib (1.6 mg kg−1 PO), it was shown to be safer 
than aspirin in regards to risk of gastric ulceration in 
healthy dogs (Sennello and Leib, 2006). In addition, 
long-term therapy of deracoxib for up to 6 months 
administered at the labeled dose, was found to be safe 
and well tolerated in dogs without any significant 
nephrotoxicity (Roberts et al., 2009). On the contrary, 
at higher than labeled doses or when given with other 
NSAIDs or corticosteroids, deracoxib has been found 
to cause gastrointestinal perforations in dogs 
(Lascelles et al., 2005). 
Even though there has been no significant 
instances of hypersensitivity reported thus far, the 
administration of sulfonamide coxibs in animals 
allergic to sulfonamides should be carefully 
considered. Indeed it might be likely a cross reaction 
with other sulfonamides such as antimicrobial or an 
evocation of hypersensitivity (Shapiro et al., 2003; 
Sanchez-Borges et al., 2004; Bergh and Budsberg, 2005; 
Ayuso et al., 2013). The hypersensitivity of sulfonamide 
coxib such as deracoxib is yet to be confirmed. 
1.3. Firocoxib 
Firocoxib (Previcox®; Meriel) was developed 
specially for the veterinary field (for dogs and horses). It 
was found to be 350~430 fold more selective for COX-2 
than COX-1 in in vitro canine whole blood assays 
(McCann et al., 2004). Chemically it is a 3-
cyclopropymethoxy-5,5-dimethyl-4-[4-(methyl sulfonyl) 
phenyl]-2-(5H)-furanone and its molecular weight is 
336.402 g moL−1. The drug was launched several years 
ago and in this short time, the pharmacokinetic 
properties of firocoxib in dogs and horses have already 
been well established (Kvaternick et al., 2007a; 
2007b; Letendre et al., 2008). Firocoxib is available 
as a chewable tablet oral preparation which has been 
approved in the European Union for dogs at a once 
daily administration of 5 mg kg−1. In addition, 
firocoxib, as an oral paste was approved by FDA for the 
control of pain and inflammation associated with 
osteoarthritis in horses at 0.1 mg kg−1 once daily 
(Kvaternick et al., 2007b). In dogs, following PO 
administration (5 mg kg−1), firocoxib was well absorbed 
and eliminated by hepatic metabolism and fecal excretion 
with an elimination half-life of 8 h (Kvaternick et al., 
2007a). Firocoxib in horses (0.1 mg kg−1) showed a 
bioavailability of 79% and an elimination half-life of 30 
and 34 h for oral and intravenous administration, 
respectively. Due to its lipophilic and non-ionizable 
nature, firocoxib was widely distributed with a volume 
of distribution value of 1.7 L kg−1 after intravenous 
administration in horse. Firocoxib showed a longer half-
life compared with other NSAIDs, such as 
phenylbutazone and flunixin meglumine (Kahn and Line, 
2010; Kvaternick et al., 2007b). 
A clinical study including 1,000 dogs treated for a 
40-day period, reported that withdrawal rate due to 
development of gastrointestinal side effects was only 
2.9%. Over 90% of investigators and owners rated 
improved clinical scores after firocoxib treatment 
(Ryan et al., 2006). In a long-term study over 52 weeks 
of treatment, a slight increase in withdrawal rate (5.1%) 
was reported due to GI signs (Autefage et al., 2011). 
Steagall et al. (2007) evaluated the adverse effects of 
oral firocoxib in healthy dogs for 29 days and found 
that a dose of 5.3±0.34 mg kg−1 of firocoxib did not 
cause any adverse effects on the GI tract or serum 
biochemical variables and was well tolerated in terms 
of hematological signs including platelet aggregation 
and buccal mucosal bleeding time index (Steagall et al., 
2007). Firocoxib was found to be effective in a 90 day 
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long-term study performed on relatively geriatric dogs 
(over 7 years) affected by osteoarthritis. The side 
effects reported (minimal biochemical changes and 
diarrhea) were thought to be due to age-related 
deterioration in liver and renal functions (Joubert, 
2009). Furthermore, in the sodium urate crystal-induced 
synovitis model, firocoxib treatment (5.3~6.49 mg 
kg−1) resulted in reduced lameness and increased 
weight-bearing at both 3 and 7 h post-treatment, as 
compared with carprofen. Firocoxib efficacy was 
similar to dogs treated with vedaprofen but without any 
cardiovascular effects (Hazewinkel et al., 2008).  
However, in developmental toxicity studies firocoxib 
showed embryotoxic and foetotoxic effects in both rats 
and rabbits, inducing a variety of malformations and 
anomalies. Consequently firocoxib, as with other coxibs, 
is contraindicated for use during pregnancy and lactation 
in dogs. Furthermore, firocoxib had a low safety margin 
in puppies compared to older dogs. Thus, like other 
drugs, its use in very young animals requires careful 
monitoring EMEA, 2006. 
1.4. Mavacoxib 
Mavacoxib (Trocoxil®; Pfizer) is a long acting coxib 
which has a chemical structure of 4-[5-(4-fluorophenyl)-
3-(trifluoromethyl)-1H-pyrazol-1-yl]-
benzenesulfonamide, it has a molecular weight of 385 g 
moL−1 and it acts as a preferential rather than selective 
COX-2 inhibitor if compared with carprofen. It is 
approved for the treatment of canine osteoarthritis 
requiring long-term treatment between 1 and 7 months 
EMEA, 2008. Mavacoxib is produced in a diverse range 
of tablets (6, 20, 30, 75 and 90 mg) as an oral chewable 
form. Unlike other coxibs, mavacoxib is recommended 
for monthly administration at 2 mg kg−1 because of its 
long half-life. In order to achieve steady-state 
concentrations, it is recommended that mavacoxib is 
administered with a 2-week interval between the first and 
second dose with monthly dosing thereafter. 
The pharmacokinetics profile of mavacoxib has been 
well described in Beagle dogs (Cox et al., 2010). It 
showed significant low clearance rate (2.7 mL/h/kg) with 
a large volume of distribution (1.6 L⁄kg) in experimental 
intravenous administration. Especially in terminal half-
life, all PO treated Beagle dogs (n = 63) showed an 
average value of 16.6 days with individual values 
ranging from 7.9 to 38.8 days. The half-life differences 
between individuals should be considered as a significant 
factor in the use of this drug. In fact, in individuals 
demonstrating a poor elimination rate this drug could 
evoke cumulative side effects. Moreover, it has been 
reported that food intake significantly affects mavacoxib 
absorption. The administration of mavacoxib (4 mg kg−1) 
in fasted and fed dogs resulted in a bioavailability of 
46.1 and 87.4% respectively. In field trials, mavacoxib 
showed a terminal elimination plasma half-life of 44 
days in the target population, however 5% of dogs had 
an extended half-life of 80 days. In addition, most 
animals treated with 2 mg kg−1, maintained trough 
plasma mavacoxib concentrations associated with 
efficacy (Cox et al., 2011). 
As the safety profile has not been established in 
reproductive toxicity, application of mavacoxib to 
pregnant or breeding animals should be avoided. 
Furthermore, this kind of drug, which has a long half-
life, should be carefully handled because of the potential 
for prolonged exposure. 
1.5. Robenacoxib 
Robenacoxib (Onsior®; Norvatis) is a coxib which 
has been developed solely for use in veterinary 
medicine and is the only approved coxib in cats available 
as a tablet as well as injectable form (King et al., 2009). 
It is recommended at a dose of 1~2 mg kg−1 once daily 
for both species. It has a chemical structure of 5-ethyl-
2-[(2, 3, 5, 6-tetrafluorophenyl)amino]-phenyl acetic 
acid and a molecular weight of 327.27. Robenacoxib 
is a weak acidic drug (pKa 4.7) which has high 
protein-binding affinity (>98% in dogs) (Jung et al., 
2009). In the in vitro COX-2 selectivity comparative 
study in dogs with whole blood assay, the IC50 ratio 
(COX-1:COX-2) was highest in robenacoxib (128.8) 
when compared to other NSAID such as deracoxib (48.5), 
nimesulide (29.2) and meloxicam (7.3) (King et al., 
2010). In cats, robenacoxib also showed more COX-2 
selectiveness (32.2) compared with diclofenac (3.9) 
and meloxicam (2.7) (Schmid et al., 2010a). 
Previous studies have revealed its pharmacokinetic 
properties via different administration routes including, 
intravenous, subcutaneous and oral administration in the 
dog and cat (Jung et al., 2009; Pelligand et al., 2012). In 
dogs, robenacoxib showed good bioavailability after oral 
(84%) and subcutaneous (88%) administration with a 
short blood half-life of 1 h (Jung et al., 2009). In 
addition, Silber et al. (2010) revealed that robenacoxib 
remained longer in inflamed synovial joints than blood. 
The anatomically focused persistence of robenacoxib 
may be triggered by its weak acidity and high protein-
binding affinity. In an inflamed area, the blood supply is 
increased and pH has become mildly acidic. These 
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alterations allow robenacoxib to enter cells more readily 
than under normal conditions. The ion-trapping due to 
the pH change slows release of the drug and as a result, 
intracellular drug concentrations increase (Brune and 
Furst, 2007). 
In a clinical study, Schmid et al. (2010b) reported that 
SC injection of robenacoxib exerted analgesic and anti-
inflammatory effects in the urate synovitis model at 
dosages of 0.25-4 mg kg−1 without COX-1 inhibition 
(Schmid et al., 2010b). In comparison with carprofen, 
robenacoxib also demonstrated good efficacy in field 
trials when given once daily (Reymond et al., 2012). 
Furthermore, robenacoxib provided similar efficacy and 
tolerability to meloxicam in controlling perioperative pain 
and inflammation in dogs (Gruet et al., 2011). In cats after 
ovariohysterectomy surgery, SC injected robenacoxib (2 
mg kg−1) provided a greater analgesic effect for up to 24 h 
compared to buprenorphine (Staffieri et al., 2013). 
According to the study from King et al. (2012), as 
expected, robenacoxib had an excellent safety profile in 
young healthy cats when administered at daily dosages up 
to 10 mg kg−1 for 28 days and up to 20 mg kg−1 for 42 
days (King et al., 2012). Also in dogs, robenacoxib 
showed high safety index without any relevant toxicity 
with daily dosages as high as 40 mg kg−1 for one 
month and 10 mg kg−1 for 6 months (King et al., 
2011). This proven safety of robenacoxib may result 
from its high COX-2 selectivity and rapid central 
compartment clearance with longer residence at 
inflamed sites (King et al., 2012). However there is no 
data on reproductive toxicity and robenacoxib should 
not be used in pregnant or breeding animals. 
1.6. Cimicoxib 
Cimicoxib (Cimalgex®; Vetoquinol) is a novel 
imidazole derivative coxib and a highly selective COX-2 
inhibitor, that has recently been launched (Emmerich, 
2012). Chemically it is a 4-[4-Chloro-5-(3-fluoro-4-
methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide 
and its molecular weight is 381.809 g moL−1. Although it 
was originally developed to treat depression and 
schizophrenia, this compound showed good oral activity 
when tested in experimental models of acute and chronic 
inflammation and pain (Haroon et al., 2012). After some 
years of human clinical studies on its anti-inflammatory 
and analgesic properties, cimicoxib was redirected from 
the human to the veterinary field. 
Cimicoxib is available as chewable oral tablets 
licensed for dogs as a once daily administration given at 
a dose of 2 mg kg−1. Due to its recent release, there is 
very little published data available. Recently an 
analytical method for cimicoxib pharmacokinetic study 
has been published (Giorgi et al., 2013). Sorbera and 
Ramis (2004) found that cimicoxib was more 
metabolically stable than celecoxib. In humans, 
cimicoxib undergoes demethylation and a subsequent 
conjugation reaction, the demethylated metabolite of 
cimicoxib has been found to be inactive in both COX-1 
and COX-2 activity assays. In rats after oral and i.v. 
administrations, biliary excretion was the major route of 
elimination. 70 and 30% of the Cimicoxib dose was 
excreted in the feces and urine respectively. In Beagle 
dogs, the bioavailability was 75% following oral 
administration (1 mg kg−1) with tmax of 2 h and t1/2 of 7 h. 
Like in rats, biliary/intestinal excretion was the major 
route of elimination in Beagle dogs and cimicoxib was 
extensively metabolized, as <0.2% unchanged drug was 
detected (Sorbera and Ramis, 2004). In an in vivo 
inflammatory acute pain model study, 10 h after 
administration (2 mg kg−1) the plasma concentrations 
were above a level of 100 ng Ml−1 (the EC50/IC50 values 
varied between 216 and 452 ng mL−1 for different 
parameters) in six out of ten animals. At 24 h, the 
concentrations are lower than the stated EC50/IC50 values 
in all animals. Considering the estimated differences in 
bioavailability and correcting for non-linear PK, it 
appeared that the effect of cimicoxib lasted for 
approximately 10-14 h in the simulated inflammatory 
acute pain model EMEA, 2009. In addition, the non-
inferiority study where it was compared with firocoxib 
confirmed that cimicoxib reduced the clinical signs of 
disease including lameness, pain, locomotor disturbance 
and oedema in dogs with chronic osteoarthritis during 
the 90 days of the follow up study. Furthermore, 
compared with carprofen, cimicoxib was also effective in 
peri-operative pain control in orthopaedic or soft tissue 
surgery during the first 24 h after surgery EMEA, 2009. 
In a 26 week tolerance study with Beagle dogs, it was 
demonstrated that adverse effects occur on the 
gastrointestinal tract and to a lesser extent the kidney 
especially papillary necrosis at higher doses (10 mg 
kg−1). However, there were no significant adverse signs 
in the recommended dose group (2 mg kg−1) and notably, 
there were no cardiovascular events. The reproductive 
toxicity study with rabbits however, revealed that the 
cimicoxib affects fertility and fetal development. Since 
there are no data in pregnant bitches, “caution” or 
“cimicoxib is contraindicated in” is needed in breeding, 
pregnant and lactating dogs EMEA, 2009. 
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2. CONCLUSION 
It is complicated work to make firm distinctions 
between preferential and selective COX inhibition or 
between nonselective and preferential inhibition. This is 
because 1. Potency ratios (COX-1:COX-2) vary widely 
according to experimental conditions both within and 
between laboratories, 2. the ratio calculated may vary 
depending on whether it is based on 50, 80, 95 or some 
other percentage inhibition and 3. apparent species 
differences in inhibition ratios (Lees et al., 2004; 
Giraudel et al., 2009). However, classification of coxibs 
is mostly academic and for the purposes of drug 
categorization. The most important thing is to understand 
the pharmaco-physiological properties of each coxib in 
order to make the appropriate choice for each situation. 
In addition, to secure the expanded list of drugs for 
veterinary use, trials for adaptation should be on going. 
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